SpeeDx and Cepheid Partner to Advance Molecular Diagnostics for Infectious Disease Management

VCBeat (WeChat Official Account: vcbeat) has learned that SpeeDx, a medical technology company specializing in molecular diagnostics, recently announced a collaboration agreement with Cepheid. Under the agreement, SpeeDx will obtain manufacturing rights for Cepheid’s GeneXpert system, which is primarily used for the ResistancePlus MG assay.

SpeeDx, founded in Sydney, Australia, in 2009, is a medical technology company focused on developing molecular diagnostic solutions. The company leverages real-time polymerase chain reaction (PCR) technology for multiplex testing, assisting physicians in diagnosing infectious diseases and assessing antibiotic resistance. SpeeDx’s product portfolio emphasizes multiplex diagnostics for sexually transmitted infections (STIs), antibiotic resistance markers, and respiratory diseases.

Headquartered in Sunnyvale, California, Cepheid is a medical technology company specializing in molecular diagnostics, dedicated to the development, manufacturing, and marketing of accurate and user-friendly molecular diagnostic tests and systems. By leveraging highly sophisticated automation to replace time-consuming manual procedures, the company has developed a genetic testing system capable of performing complex analyses on organisms. The resistance plus MG test is one of the flexible cartridge initiatives launched by Cepheid in early 2019.

ResistancePlus® MG detects Mycoplasma genitalium (Mgen) and markers associated with azithromycin resistance. Mgen is a sexually transmitted infection (STI) pathogen that can cause conditions such as urethritis, cervicitis, endometritis, and pelvic inflammatory disease. Recent studies have found that the prevalence of Mgen is higher than that of gonorrhea. Like gonorrhea, Mgen is evolving into an STI superbug, developing resistance to many antibiotics and thereby posing a threat to global public health.

Macrolide antibiotics, including azithromycin, are first-line treatments for sexually transmitted infections caused by Mycoplasma genitalium (Mgen). However, in some countries, resistance to these antibiotics has risen to 50%. Due to the growing concern over antibiotic resistance, some global STI management guidelines recommend supplementing molecular testing for Mgen with assays capable of detecting mutations associated with macrolide resistance.

A research report on using ResistancePlus MG to guide resistance-targeted therapy demonstrated that the cure rate for “Resistance+ MG” cases could be significantly increased to over 92%. This test provides clinicians with valuable diagnostic and antibiotic resistance information within a short timeframe, facilitating timely identification of resistant infections and reducing the likelihood of pathogen transmission among susceptible populations. Currently, the SpeeDx ResistancePlus MG assay has obtained CE marking in Europe and is commercially available in Europe and Australia.

Regarding this collaboration, Colin Denver, CEO of SpeeDx, stated: “The addition of ‘Resistance Plus MG’ to the flexible cartridges used in the GeneXpert system represents a compelling and exciting expansion for us. Through our central laboratory testing, patients have already benefited from resistance-guided therapy. Clinicians can now access resistance information more rapidly, supporting antimicrobial stewardship and enabling more effective antibiotic treatment decisions.”

“Cepheid’s Chief Medical and Technical Officer, David H. Persing, said: ‘We are pleased that SpeeDx is leveraging the flexible cartridge assay development process to create targeted molecular tests. With nearly 22,000 GeneXpert systems installed worldwide, this technology has the potential to be applied in a variety of settings where actionable therapeutic information is needed.’”

(Compiled by: Li Chengping)